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1. Introduction 
Proper vascular network structure is essential for normal tissue function. The vasculature 
provides oxygen, nutrients and immune cells, as well as removes tissue waste and by-
products. (Jain 2003) In tissue engineering and regenerative medicine, the existence of 
functional blood vessels is critical to the survival of the newly generated tissue. Current 
strategies for promoting new blood vessel formation, or neovascularization, have mostly 
focused on angiogenesis, which is the formation of new capillaries from pre-existing vessels 
by sprouting of endothelial cells (ECs). (Carmeliet 2003) Another mechanism of 
neovascularization, vasculogenesis, which is the in situ assembly of endothelial progenitors 
into capillaries, has also been explored as a method for stimulating new vessel formation. 
Genes or proteins of angiogenic factors have been delivered systematically or directly to a 
target tissue to promote neovascularization via either angiogenesis or vasculogenesis. For 
example, proteins from the vascular endothelial growth factor (VEGF) and fibroblast growth 
factor (FGF) families delivered by various methods have been investigated extensively for 
enhancing neovascularization. (Brey et al., 2005; Brey & McIntire, 2008)   
While the delivery of angiogenic factors has been successful in promoting new capillary 
formation, the structure of the newly formed vessels is often non-ideal. The vessels can be 
immature, with small diameters and lack of some essential cellular and extracellular 
components required for proper function. Immature vascular structure may result in poor 
blood perfusion and possibly vessel regression upon a decrease in the vascular stimulus. 
(Benjamin et al., 1999) In addition, the formation of small capillaries alone is not likely to be 
sufficient for vascularization of large, complex tissues, which are often needed for tissue 
engineering. Therefore, the goal of neovascularization in engineered tissue should be 
focused not only on the initial assembly of capillaries via angiogenesis or vasculogenesis, 
but also the expansion and stabilization of new vessels, which means the formation of 
mature, long-lasting vessels with dimensions that meet the requirement of high conductance 
blood flow. (Carmeliet & Conway, 2001) In this chapter, we will discuss current status in the 
generation of stable, long-lasting vascular networks in tissue engineering and regenerative 
medicine, identifying recent advances and limitations yet to be overcome. 
2. Angiogenesis stabilization: basic mechanisms 
The process of angiogenesis includes four stages: (a) initiation, in which a certain angiogenic 
stimulus increases vessel permeability and protein leakage; (b) progression, characterized 
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by the production of proteolytic enzymes that degrade the basement membrane (BM) lining 
endothelial cells (ECs) and surrounding extracellular matrix (ECM) to allow EC invasion 
and migration; (c) differentiation, which involves the assembly of ECs into a network with a 
luminal structure; and (d) stabilization and maturation, where mural cells (pericytes and 
vascular smooth muscle cells) are recruited and ECs deposit new BM. (Bussolino et al., 1997) 
It is important to note that the MCs may be recruited after initial network function or 
simultaneous with vessel assembly. (Brey et al., 2004) Numerous cellular and molecular 
factors are involved in the regulation of this process. Failure in this regulation could result 
in excessive vessel generation or premature regression, which is seen in many pathological 
conditions. In the following sections we will describe the basic components of the vessel and 
their role in vessel stability. 
2.1 Cells 
The walls of stable blood vessels are composed of two distinct cell types: ECs and mural 
cells (MCs). (Figure 1) While ECs form the inner lining of vascular tubes, MCs associate with 
and coat the outside of the endothelial tube. (Gaengel et al., 2008) In the case of capillaries 
the MCs, or pericytes, are intermittently present on the surface. For larger vessels the MCs, 
or vascular smooth muscle cells (VSMCs), coat the entire vessel surface often in multiple 
layers. Interactions between the ECs and MCs play a critical role in the regulation of 
vascular formation, stabilization, remodeling, and function. Abnormal interactions between 
the two cell types are implicated in a number of pathological conditions, including tumor 
angiogenesis, diabetic microangiopathy, ectopic tissue calcification, and stroke and 
dementia syndrome. (Armulik et al., 2005; Carmeliet 2003)  
 
 
Fig. 1. Process of blood vessel stabilization. Endothelial cells (EC) in immature vessels 
secrete signals that stimulate the migration and proliferation of mural cells (MC). ECs also 
secrete a thin layer of matrix, known as the basement membrane (BM) that lines the vessels 
Junctional structures, including adherent junctions and tight junctions, are present between 
ECs and provide the endothelium with integrity, mechanical strength and tightness, and a 
barrier to molecular transport. (Carmeliet 2003) During vascular sprouting, junctions are 
partially disorganized to allow cell migration and proliferation, and to increase vessel 
permeability. During vessel stabilization, junctional integrity is re-established and 
permeability is tightly controlled. (Dejana, 2004) As vessels sprout and migrate, they will 
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form branches. These sprouts then inosculate with other vessels to form complex networks. 
Typically, a high vessel density is formed in response to the initial vascular stimuli. This 
vasculature must be remodeled for tissue-specific transport and function. Apoptosis of ECs 
are involved at this later stage to remove excessive vessels. (Darland & D'Amore, 2001) 
However, excessive apoptosis may result in premature vessel regression. Growth factors, 
which are essential for angiogenesis, not only stimulate EC proliferation and migration 
but also inhibit EC apoptosis. (Dimmeler & Zeiher, 2000) Thus, the prevention of EC 
apoptosis may improve the survival and durability of blood vessels formed in engineered 
tissues. 
MCs are commonly subdivided into VSMCs, which are associated with arteries and veins 
forming multiple concentric layers; and pericytes, which are associated with small diameter 
capillaries. (Gaengel et al., 2009) Intermediate-size vessels, arterioles and venules, have MCs 
with properties between those of typical VSMCs and pericytes. Since VSMCs and 
pericytes share some common cellular markers, such as α-smooth muscle actin (α-SMA) 
and desmin, they are believed to represent phenotypic variants of the same lineage, and 
may function as progenitors for each other depending on external stimuli. (Gerhardt & 
Betsholtz, 2003)    
The presence of MCs on the surface of ECs plays a critical role in vessel stability. 
Intercellular adhesion between MCs and ECs is mediated by integrin ┙4┚1, which is 
expressed by proliferating ECs, and its ligand VCAM-1, which is expressed by proliferating 
MCs. (Garmy-Susini et al., 2005) Studies have shown that the association of MCs to the 
newly formed endothelial plexus stabilizes the vasculature, while the disruption of EC-MC 
associations results in excessive regression of vasculature. (Benjamin et al., 1998) Co-culture 
of EC with SMC in a 3D in vitro model results in a mature, quiescent EC phenotype with 
increased number junctional structures and increased resistance to apoptosis. (Korff et al., 
2001) However, the presence of MCs in the microvasculature does not always guarantee 
vessel stability. Vessels with extensive MC can still regress following loss of neovascular 
stimuli. (Brey et al., 2004) Therefore, some additional signals, such as ECM and soluble 
growth factors, are also required for vessel stabilization.  
2.2 Extracellular components 
Extracellular matrices (ECM), including BM (primarily collagen IV and various laminin 
isoforms) and interstitial matrices (typically collagen I, elastin and fibronectin but depends 
on the particularly tissue), play important roles in angiogenesis. (Francis et al., 2008) Firstly, 
the ECM scaffold provides mechanical support for ECs to form channels, preventing vessels 
from collapsing. In addition, EC adhesion to ECM regulates EC proliferation, migration, 
and survival, mediated by different signaling pathways. (Davis & Senger, 2005) And 
finally, the deposition of ECM, particularly BM, which occurs after MC recruitment 
stabilizes the vessel by decreasing permeability and preventing vessel regression. 
(Stratman et al., 2009)    
The ECM is dynamically regulated during angiogenesis. In the initiation of angiogenesis, 
ECM is degraded by proteinases, such as matrix metalloproteinases (MMPs). The 
degradation of ECM not only allows EC migration and proliferation, but also releases 
soluble growth factors trapped in the matrix. (Ghajar et al., 2008) After lumen formation, 
MCs are recruited to EC tubes and induce the deposition of new BM as well as the secretion 
of tissue inhibitor of metalloproteinases (TIMPs), which inhibit MMPs proteolysis. (Stratman 
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et al., 2009) Dysregulation of ECM, such as glycation of collagen due to diabetes and aging, 
can slow ECM vessel assembly. (Francis-Sedlak et al., 2010) 
2.3 Signaling pathways 
The formation of stable vasculature is tightly regulated by the spatial and temporal kinetics 
of numerous signaling pathways. A stable, operational vascular network results from a 
balance between signals that favor angiogenesis and vascular stabilization, and those that 
promote vascular regression. (Bussolino et al., 1997) Signaling pathways affect vascular 
stabilization presumably by regulating proliferation and apoptosis of ECs and MCs, as well 
as the deposition and degradation of ECM. (Jain 2003) In this section, we will discuss some 
of the signaling pathways and their roles in vascular stabilization. 
2.3.1 Platelet derived growth factor (PDGF) family 
The PDGF family is composed of disulfide-bonded homodimers of four subunits, PDGF-
A, PDGF-B, PDGF-C and PDGF-D, as well as the heterodimer PDGF-AB. PDGF isoforms 
exert their biological effects through the activation of two tyrosine kinase receptors, 
PDGFR-┙ and PDGF-┚, which are present on MCs and messenchymal cells. (Hellberg et 
al., 2010)  
Specifically, PDGF-BB, secreted by proliferating ECs during angiogenic sprouting, 
stimulates the migration and proliferation of MCs, which express PDGFR-┚. In addition, 
PDGF-BB induces the differentiation of messenchymal cells toward a MC lineage.(Hirschi et 
al., 1999) Genetic knockout of pdgf-b or pdgfr-β in mice results in MC deficiency, vascular 
leakage and embryonic lethality (Hellstrom et al., 1999; Lindahl et al., 1997) The more 
recently described PDGF-C and PDGF-D isoforms are also involved in vessel maturation 
and stabilization. PDGF-C drives the recruitment and differentiation of MCs resulting in 
improved BM integrity and a more mature, stable vascular wall with a lower permeability. 
(di Tomaso et al., 2009) PDGF-D induces macrophage recruitment and vessel stabilization by 
improving the SMC coating of angiogenic blood vessels and decreases their permeability. 
(Uutela et al., 2004) 
2.3.2 Angiopoietins  
The angiopoietin (Ang) family consists of Ang-1, Ang-2, Ang-3 and Ang-4. The 
angiopoietins are ligands for the Ties, a family of receptors that are expressed within the 
vascular endothelium. (Yancopoulos et al., 2000) Ang-1 is predominantly expressed by MCs, 
suggesting a paracrine mode of action; whereas Ang-2 is mostly expressed by ECs, 
suggesting an autocrine function, although expression in MCs has also been reported. 
(Gaengel et al., 2009) Ang-3 and Ang-4 are less well understood at this time.  
Ang-1 stabilizes nascent vessels and make them leak-resistant, presumably by facilitating 
interactions between ECs and MCs. Genetic deletion of Ang-1 or its receptor Tie2 in mice 
resulted in defects in vessel remodeling with poor association of ECs with BM, and failure to 
recruit MCs. (Sato et al., 1995; Suri et al., 1996) Transgenic overexpression of Ang-1 in mice 
lead to a significant increase in vessel diameter and increased resistance to vessel leakage. 
The resistance is presumably due to the ability of Ang-1 to maximize interactions between 
ECs, MCs and BM. (Thurston et al., 1999, 2000) Ang-2, on the other hand, acts as an 
antagonist of Ang-1, destabilizes vessels and contributes to vessel regression. Transgenic 
overexpression of Ang-2 disrupts blood vessel formation in the mouse embryo, resulting in 
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similar effects to Ang-1 or Tie 2 knockouts. (Maisonpierre et al., 1997) Thus, angiopoietins 
positively or negatively regulate vessel stabilization, however, the detailed mechanism of 
the signaling pathways are not yet well-described.   
2.3.3 Sphingosine-1-Phosphate (S1P) 
S1P is a bioactive lipid mediator that is primarily secreted by platelets. It activates a 
family of G-protein coupled receptors (S1P1 to 5), formerly known as endothelial 
differentiation gene (Edg)-receptors. (Gaengel et al., 2009) Mice deficient in S1P have 
severe vascular defects resulting in embryonic lethality, with incomplete coverage of 
MCs. Mice deficient in S1P1, its receptor, also showed severe defect in vascular 
maturation, suggesting the role of S1P/S1P1 signaling pathway in promoting vascular 
stabilization. (Mizugishi et al., 2005) Moreover, knockout of the EC-specific S1P1 in mice 
embryos resulted in a similar phenotype as obtained for the S1P1 full knockout, 
suggesting that S1P1 functions mainly through ECs instead of other cell types. (Allende et 
al., 2003) It was found that S1P/S1P1 signaling pathway promotes vascular stabilization 
by activation of N-Cadherin, which is a cell adhesion molecule connecting ECs and MCs. 
(Paik et al., 2004) 
2.3.4 Transforming growth factor-β (TGF-β) 
TGF- β, a growth factor family with three different isoforms TGF-β1, TGF-β2 and TGF-β3, is 
expressed by a number of cell types, including ECs and MCs. Depending on its receptor 
TGF-β mediates distinct signaling pathways. TGF-β can be both pro- and anti-angiogenic. 
(Pepper 1997) The major receptors for TGF-β in regulating vascular stabilization include 
activin receptor-like kinase (Alk)-1, Alk-5, and endoglin. (Gaengel et al., 2009)  
Activation of Alk-1 triggers EC migration, proliferation, and inhibits vessel maturation and 
MC differentiation; whereas activation of Alk-5 instead mediates inhibition of EC migration, 
reduced proliferation, increased vessel maturation and MC differentiation, suggesting that 
TGF-β regulates vessel maturation and stabilization via a balance between Alk-1 and Alk-5. 
(Goumans et al., 2002) The determination of which signaling pathway TGF-β activates 
appears to depend on its concentration. At low doses, TGF-β promotes EC proliferation by 
activating TGF-β /Alk-1 pathway; while at high doses, Alk-5 is activated instead. (van den 
Driesche et al., 2003) Endoglin, a TGF-β co-receptor expressed specifically in ECs, modulates 
Alk-1 and Alk-5 mediated pathways, possibly by favoring the TGF-β/Alk-1 pathway. 
(Letamendia et al., 1998)  
2.3.5 Vascular endothelial growth factor (VEGF) family 
VEGF is a family of angiogenic growth factors expressed by a variety of cells, including 
keratinocytes, macrophages, mast cells, vSMCS, and ECs. Members of the VEGF family 
include VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF). VEGF is a 
major mitogen for ECs, mediated via VEGF tyrosine kinase receptors (VEGFRs) expressed 
on ECs. (Bussolino et al., 1997; Yancopoulos et al., 2000) It has been shown that VEGF plays a 
central role in neovascularization by stimulating ECs proliferation, migration and increasing 
vascular permeability in a number of physiological and pathological processes. (Nor et al., 
1999)  
However, the role of VEGF in regulating vascular stabilization can be both positive and 
negative, depending on its spatial and temporal kinetics. On the one hand, VEGF enhances 
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EC survival and protects EC from apoptosis by up-regulating the expression of Bcl-2 (B-cell 
lymphoma 2), an apoptosis regulator protein. (Nor et al., 1999) Withdrawal of VEGF prior to 
stabilization and remodeling may result in excessive vessel regression by EC apoptosis. 
(Benjamin et al., 1999; Jain, et al., 1998) On the other hand, VEGF is also considered as a 
negative regulator for vessel maturation by disrupting VSMC function and pericyte 
coverage of nascent vascular sprouts, leading to vessel destabilization. (Greenberg et 
al.,2008). The overexpression of VEGF results in leaky, immature and unstable vessels, 
which contribute to a number of pathological conditions, such as tumors, diabetic 
retinopathy, and age-related macular degeneration (AMD). Therefore, the dosage of 
VEGF must be tightly regulated in a spatial, temporal and quantitative manner in 
therapeutic applications to avoid abnormal or aberrant vascular structure. (Yancopoulos 
et al., 2000) 
2.3.6 Ephrins and notch 
Ephrins and Notch are two signals that are generally involved in the differentiation of many 
cell types. In angiogenesis, the two signaling pathways are involved in the determination of 
arterio-venous vessel fate. (Jain 2003) Thus, the ephrins and Notch signaling pathways are 
considered novel targets for therapeutic angiogenesis. (Sullivan & Bicknell, 2003; Cristofaro 
& Emanueli, 2009) The ephrin ligands and Eph receptors are both transmembrane molecules 
expressed on ECs and other cell types.(Yancopoulos et al., 2000; Cristofaro & Emanueli, 
2009) The ligand ephrin-B2 is expressed specifically in the arterial endothelium, while the 
receptor EphB4 expresses in the venous endothelium. The distribution suggest a role in 
defining boundaries between arterial and venous domains. (Adam et al., 1999; Wang et al., 
1999). Notch is a family of transmembrane protein receptors that bind to ligands 
Delta/Serrate. The Notch pathway, in angiogenesis, is also required for arterial-venous 
differentiation. (Sullivan & Bicknell, 2003; Gaengel et al., 2009) Activation of Notch signaling 
leads to repression of venous cell fate in EC, while ablation of Notch function resulted in 
defects in blood vessel formation similar to those associated with improper arterial-venous 
specification. (Lawson et al., 2001; Liu et al., 2003) 
2.3.7 Others 
There are a number of other signaling pathways involved in the formation of stable 
vasculature. For example, brain derived neurotrophic factor (BDNF) is a neurotrophin for 
neuron survival and differentiation. It is also an EC survival factor involved in 
intramyocardial vessel stabilization, by activation of trk B receptors expressed on cardiac 
microvascular ECs.(Donovan et al., 2000) Monocyte chemotatic protein-1 (MCP-1) is a small 
cytokine best known for its ability to recruit monocytes after injury. However, recent studies 
have shown that MCP-1 improves vessel stabilization during angiogenesis by promoting 
MC recruitment and inducing VSMC proliferation. (Aplin et al., 2010; Selzman et al., 2002) 
Nitric oxide (NO), a multifunctional gaseous molecule that regulates various physiological 
functions is also involved in vascular stabilization. An in vivo tissue-engineered blood vessel 
model revealed that NO mediates EC-MC interaction and induces MC recruitment, vessel 
branching, and longitudinal extension and subsequent stabilization of the vessels. 
(Kashiwagi et al., 2005) A summary of the of numerous signalling pathways is provided in 
Table 1, with ligand/receptor pairs, cells that express these molecules, and their roles in 
vessel maturation and stabilization.  
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Ligand (Cells) Receptor (Cells) Roles in vessel stabilization 
Ang-1 (MCs) Tie2  
(ECs, MSCs) 
Stabilizes vessels by mediating EC-MC and EC-
ECM adhesion; Induces production of factors 
such as HB-EGF, HGF and MCP-1. 
Ang-2  
(ECs) 
Tie2  
(ECs; MSCs) 
Destabilizes vessels  by binding to Tie2 to 
attenuate the effect of Ang-1. 
Bcl-2 (ECs) ERKs (ECs) Prevents EC apoptosis and enhances vessel 
durability. 
BDNF (neurons; 
ECs) 
Trk-B (neurons; ECs; 
MCs ) 
Promotes intramyocardial arteries and capillaries 
stabilization by enhancing EC survival during 
embryogenesis.  
Delta/Serrate 
(ECs) 
Notch (ECs) Determines arterial-venous fate of ECs by 
repressing venous fate in arterial ECs. 
Ephrin-B2 
(Arterial ECs)  
Eph-B4 (Venous ECs)
 
Determines arterial and venous EC 
specialization. 
HB-EGF (ECs) ErbB1, ErbB2 (MCs) Promotes MCs proliferation and protects from 
apoptosis, involved in Ang(s) regulation. 
HGF  
(ECs, MSCs) 
C-met  
(ECs, SMCs) 
Induces SMC migration, mediating angiopoietins 
regulated vessel stabilization. 
MCP-1  
(ECs, MCs) 
CCR-2  
(MCs) 
Mediates spontaneous and Ang-1 induced MC 
recruitment. 
PDGF-BB (ECs) PDGFR-┚ (MCs; 
MSCs) 
Promotes MC migration and proliferation; 
Induces MSCs differentiation to MCs. 
S1P (Platelets) S1P1  
(MCs) 
Activates adhesion molecule connecting ECs and 
MCs; directs MC recruitment and association to 
vessels. 
Alk1  
(ECs; MSCs) 
Promotes EC migration and proliferation; 
Inhibits vessel maturation and MC 
differentiation. 
Alk5  
(ECs; MSCs) 
Induces MC differentiation and ECM production; 
Inhibits EC migration and proliferation. 
TGF-┚  
(ECs; MCs) 
Endoglin (ECs) Modulates Alk-1 and Alk-5 mediated pathway 
by favoring Alk-1. 
VEGF 
(Macrophages; 
MCs; fibroblasts) 
VEGFRs (ECs)  Enhances EC survival by inducing Bcl-2 
expression; Inhibits MC association and increases 
vessel permeability. 
Table 1. Signaling Pathways Regulating Vessel Stabilization 
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Many of the signaling pathways mentioned above work in a coordinated fashion to regulate 
vessel stabilization. For example, MCP-1 was found to be one of the many cytokines 
released during angiopoietin induced MC recruitment.(Aplin et al., 2010) Other cytokines 
involved in angiopoietin function include EC-derived heparin binding-epidermal growth 
factor (HB-EGF) (Iivanainen et al., 2009; Stratman et al., 2010) and hepatocyte growth factor 
(HGF) (Kobayashi et al., 2006). PDGF-BB was found to promote MC proliferation partially 
by inducing the release of fibroblast growth factor-2 (FGF-2), which in turn transactivates 
FGFR-1. (Millette et al., 2006) PDGF-B stimulation also induces an acute production of TGF-
β, which in turn, negatively regulates Ang-1 expression induced by the PDGF-B stimulation. 
(Nishishita & Lin, 2004) Thus, a complex interaction of multiple signaling pathways is 
required to maintain vascular homeostasis and vascular stabilization. 
3. Tissue engineering strategies 
Extensive attention has been given to tissue engineering for its potential to restore, maintain 
or improve tissue functions. (Langer & Vacanti, 1993) However, the clinical application of 
engineered tissues requires the ability to form extensive, stable microvascular networks 
within engineered tissues. (Brey & McIntire, 2008) While strategies for neovascularization, 
including angiogenesis, vasculogenesis and arteriogenesis, have been extensively reviewed 
elsewhere (Brey et al., 2005; Ennett & Mooney, 2002; Sneider et al., 2009), increased attention 
is being given to the later stage of neovascularization, which is the maturation and 
stabilization of newly formed vessels. Different tissue engineering strategies, including 
protein delivery, gene therapy and cell therapy (Table 2) have been developed and tested in 
both in vitro and in vivo models.   
 
 Advantages Disadvantages 
Protein 
Delivery 
Better dose control than gene therapies; 
Temporal control over release can be 
achieved with certain delivery systems. 
Expensive to produce and isolate 
proteins;  
Short protein half-lives in vivo; 
 
Gene 
Therapy 
Long-term active growth factor 
expression; 
Delivery restricted to area of modified 
cells 
Safety issues based on delivery 
methods; 
Difficult to control the level and 
duration of gene expression; 
Limited transfection efficiency. 
Cell 
Therapy 
Introducing cell population that is 
sensitive to stimuli unlike many cells in 
the disease/damaged tissue  
Cells can stimulate neovascularization by 
incorporation into new vessels or release 
of soluble factors 
Costly and time consuming for cell 
isolation and expansion; 
Limited cell sources for autologous 
transplantation; 
Immunosuppresive medications 
needed for allogeneic or exnogeneic 
transplantation. 
Table 2. Advantages and Disadvantages of General Strategies for Promoting Stable 
Neovascularization in Engineered Tissues 
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3.1 Protein delivery 
3.1.1 Single factor delivery 
The formation of a stable vascular network during normal healing involves a complex 
spatial and temporal regulation of a large number of angiogenic stimulators and inhibitors. 
(Jain, 2003) While it may seem logical that all of these factors would be required in order to 
generate vessels in engineered tissues, researchers have attempted to initiate the entire 
process through the delivery of a single factor. Members of the VEGF and FGF families were 
some of the first identified angiogenic growth factors and have been used in clinical trials 
for the treatment of limb ischemia. (Cao et al., 2005) However, the short term delivery of 
basic FGF (FGF-2) or VEGF may result in immature vessels, stable for only a short time prior 
to regression. (Dellian et al., 1996) Based on these issues others have chosen to use factors 
with a known role in angiogenesis stabilization. For example, PDGF-BB, Ang-1, HGF, and 
ephrin-B2 are some of the factors  currently under investigation in animal and in vitro 
models. (Brey & McIntire, 2008) 
It is possible that the short lifetime and immaturity exhibited by vessels stimulated in these 
cases is not the result of using only a single factor, but instead due to the transient nature of 
their presence. The short lifetime of proteins and their rapid transport out of tissues can 
results in only a short-term stimulus. A single protein delivered in a controlled manner may 
be able to provide enough signal to prolong the vascularization response and, possibly, 
increase vessel maturation. A number of delivery systems, including natural and synthetic 
biomaterials, have been developed for growth factor delivery. Commonly used materials 
include naturally occurring materials, such as alginate, gelatin and fibrin, as well as 
synthetic materials, such as poly (lactic-co-glycolic acid) (PLGA), and modified polyethylene 
glycol (PEG). Sustained growth factor delivery can be achieved and controlled using those 
materials in the form of hydrogels, micro/nano particles, fibers, porous matrix, or their 
combinations. (Chen & Mooney, 2003; Zisch et al., 2003a) The materials can be used to 
modulate delivery via diffusive resistance or through direct interactions between the 
materials and the growth factors. For example, the release of FGF-1 encapsulated in alginate 
microbeads can be modulated based on alginate composition. The release of FGF-1 from this 
relatively simple biomaterial can result in significantly prolonged increase in vascular 
density compared to a bolus injection of FGF-1. The enhancement in neovascularization can 
persist for greater than 6 weeks. In addition, release of FGF-1 from alginate can lead to a 
greater number of capillaries interacting with MCs but the fraction of MCs was not changed. 
(Moya et al., 2009, 2010) 
In addition to diffusion-controlled release, molecules can also be covalently immobilized to 
a polymeric surface or matrix for growth factor delivery and presentation. For example, 
VEGF has been covalently bound to fibrin gels resulting in cell demanded release. The 
immobilized VEGF cannot diffuse out and is only released as the fibrin is degraded. 
Compared to VEGF that diffuses from the fibrin gels, which formed leaky and chaotic 
vessels, the VEGF immobilized fibrin gels were able to stimulate the formation of nonleaky, 
organized vasculature with MC coverage and BM deposition. (Ehrbar et al., 2004) Synthetic 
polymer matrixes have also been used for immobilized growth factor delivery. PEG 
hydrogels modified with MMP sensitive degradation sequences and cell adhesion sequences 
have been used in combination with a number of growth factors, including VEGF (Leslie-
Barbick et al., 2011; Moon et al., 2010; Zisch et al., 2003b), Ephrin-A1 (Moon et al., 2007), and 
PDGF-BB (Saik et al., 2011). Capillary-like structures were formed only in the contact area 
with the immobilized VEGF in vitro, while after in vivo implantation, functional vessels were 
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formed with MC coverage. (Moon et al., 2010) Compared to single dose delivery, the 
sustained delivery of growth factors allows a more precise spatial control over the 
formation of vascular networks and may be able to lead to a more persistent vascular 
response and mature vessel formation even in the absence of additional maturation 
factors. 
3.1.2 Multiple factors delivery 
Since the formation of a stable vascular network appears to require the collaboration of a 
number of growth factors, the delivery of a combination (cocktail) of angiogenic molecules 
has been investigated as a method for improved vascular maturation. For example, co-
delivery of both FGF-2 and VEGF from an accellular collagen-heparin scaffold resulted in 
higher vessel density and more MC covered mature vessels, compared to single factor 
delivery. (Nillesen et al., 2007) In addition, some of the molecules involved in the 
angiogenesis stabilization signaling pathways (Table 1) have been delivered to the target 
tissue together with stimuli involved in the initiation step. PDGF-BB, a signaling protein 
stimulating MC proliferation and recruitment, has been used in combined delivery with 
VEGF (Chen et al., 2007; Richardson et al., 2001) and FGF-2 (Cao et al., 2003; Lu et al., 2007). 
Tested in many animal models, the dual delivery of PDGF-BB, a vessel maturation factor, 
with VEGF or FGF-2 resulted in not only an increase in vessel quantity, but also improved 
vessel quality. In a mouse corneal micropocket model, the dual delivery of PDGF-BB with 
FGF-2 led to stable vessels lasting for more than a year, while vessels formed by single 
delivery of PDGF-BB or FGF-2 regressed within 70 days (Cao et al., 2003). Other vessel 
maturation factors, such as Ang-1 (Peirce et al., 2003) and S1P (Tengood et al., 2010), have 
also been investigated in combined delivery systems with VEGF resulting in stable, long-
lasting vessels compared to VEGF delivery alone.  
Moreover, it appears that in dual factor delivery, the sequence of the molecules 
administrated matters. Angiogenic factors, such as VEGF and FGF, are involved in the 
initial stages of angiogenesis primarily acting on ECs, while vessel maturation factors, such 
as PDGF-BB, Ang-1 and S1P, are involved in the later stage of vessel stabilization, mostly 
targeting MCs. Therefore, a temporal separation for distinct kinetics is likely preferred with 
initial administration of angiogenic factor(s) followed by a vessel maturation factor(s). The 
sequential delivery of VEGF followed by S1P (Tengood et al., 2010) and FGF-2 followed by 
PDGF (Tengood et al., 2011) resulted in increased vessel density and stability compared to 
simultaneous dual delivery. A reverse in the sequential delivery results in decreased vessel 
density and stability, presumably due the factors working against each other. It was 
proposed that early delivery of vessel maturation factors restricts EC tube formation and 
expansion, resulting in decreased vessel density and vessel diameter. The late delivery of 
angiogenic factors was thought to then inhibit MC recruitment, resulting in excessive 
formation of immature vessels susceptible to regression. (Tengood et al., 2010, 2011)  
With certain modifications, sequential delivery of multiple growth factors can be achieved 
with delivery materials. For example, alginate can be made into multilayer microbeads with 
an internal region for slow protein release and external layer for faster protein release. 
(Khanna et al., 2010) PLGA, a biodegradable copolymer, can be made into microspheres 
encapsulated porous matrix, in which the microspheres are loaded with factor required for 
later stage of angiogenesis (PDGF-BB) with slow release kinetics, while the porous matrix is 
loaded with factor required for initial stage of angiogenesis (VEGF) with fast release rate. 
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(Carmeliet & Conway 2001; Richardson et al., 2001) Although the temporal and spatial 
kinetics of the growth factor(s) delivered to the target tissues can be controlled using certain 
delivery systems, there are still limitations existing with this strategy. The production and 
purification of massive amounts of active protein factors can be very expensive. And since 
most growth factors have relatively short half-lives, their bioactivity can be compromised 
due to storage, delivery routes, and metabolism in vivo. Moreover, the optimal combination 
and concentration of growth factors for different engineered tissues and the any side effect 
after long-term administration still need to be identified. 
3.2 Gene delivery 
3.2.1 Genes 
While the use of protein delivery offers improved control of the dose for the growth factors, 
there are also some disadvantages for those strategies, including expensive mass production 
of the proteins, and short protein half lives in vivo. Those limitations can potentially be 
overcome by means of gene therapy. (Rissanen et al., 2001) Gene therapy allows prolonged 
overexpression of proteins, theoretically leading to sustained therapeutic effects after a 
single application, with minor change in systemic growth factor concentrations. (Gosh et al., 
2008) Therefore, DNA sequences encoding for growth factors involved in angiogenesis can 
be used to improve neovascularization. In this section, we will only review genes used 
directly to the testing model or patients, either by systemic or local injection, or release from 
polymeric system. Genetic modification to cells for neovascularization will be introduced in 
the following section, cell therapies.   
Transient vegf gene expression in vivo results in potent angiogenic sprouting, however, the 
resulting vasculature appears to be immature and leaky, similar to the results of VEGF 
protein delivery. (Rissanen et al., 2003) When vegf gene is co-administrated with genes 
encoding angiogenic maturation factors, such as pdgf-b (Hao et al., 2004a; Korpisalo et al., 
2008; Kupatt et al., 2010) and ang-1 (Chen et al., 2007; Siddiqui et al., 2003; Su et al., 2009), the 
vasculature is longer-lasting and less permeable,with increased perfusion, which is also 
similar to the results of dual protein growth factor delivery. Other genes delivered for stable 
vascular networks formation includes ang-1 (Shyu et al., 1998), pdgf-b (Shea et al., 1999), fgf-2 
with pdgf-b (de Paula et al., 2009; Hao et al., 2004b), inf-β (Dickson et al., 2007), and neutrophin-
3 (Cristofaro et al., 2010).  
3.2.2 Vectors 
Vectors are needed in order for the genetic material to be transferred into cells and 
expressed. Commonly used vectors for gene delivery are plasmids and viral vectors. 
(Rissanen et al., 2001) Plasmids are DNA sequences that can automatically repeat and 
express in a host cells. They are easy to manufacture in a large quantity, and have low 
toxicity with a low immune response. However, naked plasmid DNA usually has very low 
transfection efficiency except in muscle tissue, therefore biomaterials have been used to 
increase plasmid-based gene transfer efficiency. (Yia-Herttuala & Alitalo, 2003) For example, 
PLGA, a degradable copolymer that has been widely used as a tissue engineering scaffold 
and drug delivery vehicle, has been applied as a carrier for plasmid. PLGA can be made into 
nanoparticles with the modification of cationic polymer chitosan to increase plasmid 
transfer efficiency. (Tahara et al., 2008) It can also be prepared as a matrix for sustained 
plasmid delivery, which in turn, results in longer term growth factor expression. (Nie et al., 
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2008) Viral vectors, on the other hand, have much higher transfection efficiency compared to 
naked plasmids, but have significant safety concerns. Adenoviruses (Levanon et al. 2006) 
and adeno-associated viruses (AAV) (Arsic et al., 2003) are the most commonly used viral 
vectors for growth factor gene delivery. While adenoviral vectors may cause inflammatory 
reactions and lack sustained expression, AAV only causes a very mild immune response 
and has shown long-term transgene expression, which makes it more attractive in gene 
therapy. (Dickson et al., 2007)  
Despite the success of gene therapies for the formation of stable vasculature in some animal 
models, clinical efficacy has yet to be observed. The pharmacokinetics and 
pharmacodynamics of gene vectors and products remain largely unknown and difficult to 
control. In addition, data from long-term follow up of clinical studies is lacking. (Yia-
Herttuala & Alitalo, 2003) Moreover, the method of gene delivery must be carefully selected 
to balance the need for maximum transfer efficiency with minimum risk of vector related 
safety issues. (Brey & McIntire, 2008) 
3.3 Cell therapies 
Although the delivery of growth factors or their genes has shown great potential to activate 
the host angiogenic response, certain pathological conditions may also require the 
transplantation of appropriate blood vessel forming cells, due to loss of, or damage to, the 
host vascular cells. In addition, these cells may rapidly assemble into vessels which can 
inosculate with the host, decreasing the time required for tissue perfusion relative to 
protein/gene approaches. In cell therapies, the cells would have to be isolated from donor 
or host sources, expanded and implanted into the target tissue, where the cells proliferate 
and incorporate into functional vessels. (Ennett & Mooney, 2002) ECs are of great interest in 
this strategy for their potentials to mimic vasculogenesis and assemble into capillary 
structures, as well as to release multiple angiogenic factors following implantation. (Brey et 
al., 2005, 2008) Transplantation of mature ECs have been shown to increase 
neovascularization in engineered tissues. (Nor et al., 2001) However, the limited availability 
and proliferation capability of mature ECs limtis this approach. (Kim & von Recum, 2008) 
Therefore, a number of other cell types and modifications may be needed in addition to the 
used of mature ECs for stable vasculature formation.  
Recent preclinical studies have shown that stem and progenitor cells derived from embryos 
or adult bone marrows have the potential to restore tissue vascularization after ischemic 
events. (Rafi & Lyden, 2003) Unlike mature cells, stem and progenitor cells have the 
potential to self-renew and differentiate into multiple cell types. While mature ECs seeded 
into collagen-fibronectin gels and implanted into different animal models suffered from 
poor perfusion and fast regression (Au et al., 2008b; Koike et al., 2004), ECs derived from 
human embryonic stem (hES) cells formed durable and functional blood vessels in vivo, 
supporting perfusion for over 150 days. (Wang et al., 2007) Co-delivery of ECs with 
mesenchymal stem cells (MSC) can also result in stable and functional vessels, lasting for 
more than 130 days, which was not achieved when either of the cell types were used alone. 
(Au et al., 2008a) 
Endothelial progenitor cells (EPCs) derived from circulating blood or bone marrow have 
also been used to introduce neovascularization in vivo. (Park et al., 2004) However, in order 
to form stable and durable vascular network, EPCs are often co-implanted with other cell 
types, such as VSMCs (Melero-Martin et al., 2007) or mesenchymal progenitor cells (MPCs) 
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(Melero-Martin et al., 2008). EPCs are expected to form the lumen of new vessels and 
VSMCs/MPCs serve as perivascular cells adjacent to the lumen providing survival and 
stability signals. EPCs derived from adult peripheral blood (PB) as well as umbilical cord 
blood (CB) have been compared for their ability to form functional long-lasting vessels in 
vivo. When co-implanted with 10T1/2 cells, a type of mouse MPCs, PB-EPCs and CB-EPCs 
both formed new vessels. While PB-EPCs formed vessels were unstable and regressed in 3 
weeks, CB-EPCs formed normal-functioning vessels that lasted for more than 4 months, 
possibly due to a greater proliferative capacity of these cells. (Au et al., 2008b) Therefore, CB-
EPCs hold great potential for their ability to form stable vasculature in engineered and 
regenerated tissues. Adipose-derived stromal cells (ASCs) have also been investigated as 
another potent candidate for neovascularization cell therapy, due to their ability to stimulate 
angiogenesis as well as vessel maturation in vivo. (Rubina et al., 2009) 
Cell therapies can also be used in combination with single or multiple growth factors or 
their genes to improve the function of the transplanted cells. Stromal cell derived factor-1 
(SDF-1), a small chemokine involved in recruiting EPCs, was delivered in combination with 
EPCs to promote EPC engraftement in ischemic muscle. (Kuliszewski et al., 2011; Yu et al., 
2009) Dual delivery of VEGF and MCP-1 from alginate microbeads has been shown to 
support EC transplantation, with VEGF improving survival of transplanted ECs and MCP-1 
inducing MCs recruitment. (Jay et al., 2010) A similar effect was observed when co-
delivering FGF-2 and granulocyte-colony stimulating factor (G-CSF) with bone marrow 
cells transplanted in a rodent model of critical limb ischemia. While FGF-2 directs EC 
migration and proliferation, G-CSF promotes the homing of bone marrow stem cells (in 
particular EPCs) to the ischemic site. (Layman et al., 2011) PLGA microparticles loaded 
with VEGF and hepatocyte growth factor (HGF), as well as Ang-1, were delivered in 
combination with cord blood derived vasculogenic progenitor cells. The delivery of triple 
growth factors significantly enhanced the effect of cell therapy in multiple animal models, 
with increased progenitor cell incorporation, improved vessel function, and stabilization. 
(Saif et al., 2010)  
In addition to combined gene or protein delivery with cells, ECs and EPCs can also be 
genetically modified ex vivo prior to implantation to enhance vascular stabilization. For 
example, Bcl-2 is an anti-apoptosis protein that is upregulated during angiogenesis. ECs 
transfected with the bcl-2 gene to inhibit EC apoptosis have shown increased vascular 
density and stability. Vessels formed with bcl-2 transduced ECs connect with host 
circulation and last for at least 2 months. (Enis et al., 2005; Schechner et al., 2000; Shepherd et 
al., 2009) EPCs with vegf gene overexpression have been shown to increase EPC migration 
and reduce serum starvation-induced apoptosis in vitro. (Yu et al., 2009) When implanted in 
vivo, the vegf transfected EPCs stimulated greater blood flow and angiogenesis in animal 
models of ischemia than EPCs alone. (Ikeda et al., 2004)  
In spite of the promising results seen with cell therapies, certain limitations still exist. First, 
the sources of cells for transplantation, either mature cells or progenitor cells, can be 
problematic. If autologous cells have to be used, there are usually limited number of cells 
available, not to mention that their viability and activity are compromised due to disease or 
aging of the patient. (Brey & McIntire, 2008) If allogeneic and xenogeneic cells can be used, 
they would initiate a host immune response, which requires immunosupressive medication, 
making the patient vulnerable to infection and other diseases. Secondly, the expansion of 
isolated cells ex vivo can be costly, time-consuming and technically challenging. If mature 
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ECs and VSMCs are used for transplantation, it often requires longer times to reach a 
sufficient number, due to their low self-renewal capability. Stem and progenitor cells, on 
the other hand, have much higher proliferation rate. However, the expansion of these cells 
while maintaining their multipotency may be a technical challenge. (Ennett & Mooney, 
2002) In addition, determination of the optimal cell types and concentration, delivery 
route, as well as identifying growth factors or genes to couple with cell transplantation 
requires further research. And lastly, the exact roles and ultimate fates of the transplanted 
cells remain largely unknown. Whether or not the transplanted cells would cause some 
other adverse complications, such as tumor angiogenesis, atheroma formation and 
retinopathies, is still unknown. (Rafii & Lyden, 2003) Those questions need to be 
answered with preclinical studies before proceeding to extensive clinical applications.  
3.4 Analytical methods 
3.4.1 In vitro models 
In order to investigate the efficacy of different tissue engineering strategies for 
neovascularization, a serial of preclinical tests should be done with different analytical 
models before jumping to any conclusion and proceeding with patients. In vitro models are 
usually used to allow the evaluation of a single or a combination of factors (protein, gene or 
cells) in a relatively simple, robust, and controlled system. Most early in vitro models of 
neovascularization only used ECs to spontaneous form tubes in a 2D or 3D environment to 
mimic angiogenesis or vasculogenesis. (Francis et al., 2008) Those models have been used to 
investigate the effect of soluble or insoluble factors, as well as genetic manipulation to the 
formation of new vessels in vitro. However, since the stabilization and remodeling stage of 
angiogenesis involves the interaction between ECs and MCs, many later studies have 
incorporated SMCs co-cultured with ECs. ECs and SMCs with a defined number can be co-
cultured as a spheroid and put into a 3D scaffold. By fluorescently labeling the two cell 
types with different dyes, the cells can be visualized and distinguished under fluorescence 
microscope. The coculture spheroid can spontaneously organize into a core of SMCs and a 
surface layer of ECs, which is a spherical mimic of cylindrical blood vessels where there is a 
surface of ECs and coating MCs. (Korff et al., 2001) This model allows study of the 
interactions between ECs and SMCs and their roles in angiogenesis and vessel stabilization. 
(Brey et al., 2005)  
Another in vitro model commonly used in studying angiogenesis and vessel stabilization is 
called aortic ring assay. (Nicosia & Ottinetti, 1990) The model results from the isolation of a 
1-2 mm cross-section of aorta from rats or mice which is then embedded in a 3D biomaterial. 
Under certain stimuli, new vessels form with an inner core of ECs and a outer layer of MCs, 
which can then be visualized by immunofluorescent staining for different cellular markers. 
By treating the culture with vessel maturation factors, such as Ang-1 and MCP-1, increased 
MC recruitment was observed in this model. (Aplin et al., 2010; Iurlaro et al., 2003) However, 
since the model uses an organ part with multiple cell types, many other undefined cell types 
can also contribute to the network formation. It is difficult to isolate the contribution of each 
cell type in this model. (Brey et al., 2005) 
3.4.2 In vivo models 
While the in vitro models provide convenient evaluation methods for the study of vessel 
assembly, the controlled environment differs dramatically from the actual in vivo 
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environment where other factors, such as blood flow, inflammatory response, endocrine 
regulation, etc. contribute to the process. Therefore, studies with in vitro models are often 
followed by in vivo studies. A number of in vivo models have been developed to isolate the 
process of neovascularization, with different aspects of focus in different organ systems. 
Commonly evaluated parameters in most in vivo models include: vessel density, SMC 
coverage rate, vessel lasting or regression time, vessel size distribution, blood perfusion rate, 
vessel permeability, etc.  
Subcutaneous implantation of scaffold materials is a commonly used method to evaluate 
protein, gene or cell therapies. (Jay et al., 2010; Shea et al., 1999; Tengood et al., 2010) Growth 
factors, genes or cells can be embedded a matrix material, which will then be implanted 
subcutaneously to animals as a "plug". The presence of therapeutic agents will affect local 
neovascularization and tissue invasion into the material. At different time points after the 
implantation, local tissues will be harvested for evaluation. Typically histologic analysis of 
vessel density, diameter, and SMC coverage are performed, but more sophisticated 
techniques such as confocal microscopy, vascular casts, and microCT following contrast 
enhancement can be used to provide a better understanding of vascular structure. This 
model is relatively easy to use, and can be applied to evaluate different therapeutic 
strategies. However, all animals need to be sacrificed in order for the neovascularization 
assessmment, and it only provides the evaluation of some basic parameters. Therefore, other 
animal models are often used to provide greater detail into the process.   
The mouse corneal micropocket assay allows for monitoring neovascularization without 
sacrificing animals. The method has been used by Cao et al. for the evaluation of vascular 
stability in response to dual growth factor delivery. Briefly, growth factor-loaded 
micropellets are implanted into a mouse corneal micropocket. Vessel lengths and 
vascularization areas of the eyes can be measured at various time points. The method allows 
the observation of neovascularization frequently without invasive surgery, thus limiting the 
number of animals used. Moreover, it allows long-term observation of vessel persistence. 
This method has only been used for evaluating growth factors or gene delivery, either as 
soluble factors (Cao et al., 2003; Lai et al., 2001; Lu et al., 2007) or immobilized in a hydrogel 
(Moon et al., 2010; Saik et al., 2010). Use of this model to evaluate cell therapies is still rare to 
our knowledge. On the other hand, cranial windows model of severe combined 
immunodeficient (SCID) mouse has been used to evaluate cell therapies. (Au et al., 
2008a,b; Wang et al., 2007) Similar to the corneal model, the cranial windows model also 
allows observation of neovascularization for several months without sacrificing the 
animals.  
Mice, rats or rabbits hindlimb ischemia models have been used to evaluate the efficacy of 
protein delivery, gene therapy and cell therapy in neovascularization. (Cao et al., 2003; de 
Paula et al., 2009; Laymen et al., 2011) The model applies ligation to the femoral artery and 
its branches to create ischemia in one limb. This model attempts to mimic peripheral arterial 
occlusive disease (PAOD), however this model only recreates the ischemic event and not the 
chronic vascular disease that lead to the condition in humans. After a certain treatment 
strategy, a number of neovascularizaiton parameters can be assessed, including flow 
recovery rate. The intensity of blood perfusion in the created ischemic area can be 
measured with different imaging techniques include laser Doppler or after systemically 
injection of fluorescent- or radio-labeled particles. Another ischemic model is the 
myocardial infraction heart model. Instead of femoral artery, the left anterior descend 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
492 
artery (LAD) is ligated in the animal to create ischmia. (Hao et al., 2004) Besides common 
neovascularation parameters, cardiac morphology and function can also be evaluated 
using this model.  
There are also a number of other animal models used in evaluating angiogenesis and 
vascular stability. The chorioallantoic membrane (CAM) model with chicken or quail 
embryos is a simple method to evaluate vascularization in response to different therapies. 
(Saif et al., 2010; Stratman et al., 2010) After therapeutic agents injection or implantation, the 
angiogenic effect can be easily assessed by imaging vascular regions of the CAM. This 
model is cost efficient and easy to perform compared to other mammalian animal models. 
Suitable animal models should be selected based on the target function of the therapeutic 
strategy. In most cases, one single animal model may not be sufficient to testing all the 
aspects of interest in neovascularization, therefore multiple in vivo models may be required 
to provide extensive understanding of the potential strategy. In addition, if the technique is 
ultimately prepared for a specific tissue engineering application then the appropriate pre-
clinical model of the diseased or damaged tissue should be used.  
4. Conclusions  
The formation of stable vascular networks is critical for the survival of regenerated tissue in 
tissue engineering applications. In many cases, current strategies can result in immature 
vessel formation, providing poor perfusion and eventually leading to vessel regression. 
Recent studies have focused more on the later stage of neovascularization, which is the 
stabilization and remodeling of new vasculature. The process is highly regulated by both 
soluble and insoluble factors. Studies in the cellular and molecular mechanisms involved in 
vascular maturation have provided insight towards the development of strategies for the 
formation of stable vascular networks in engineered tissues. Successes have seen in many 
preclinical studies with these strategies; however, future success requires collaboration 
from interdisciplinary fields, including molecular and cellular biology, engineering and 
medicine.  
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